CD276 and allergic disease: For a minority of individuals predisposed to an allergic reaction, the previous exposure to murine anti-B7H3 therapy in cycle 1 may “prime” or sensitize them by stimulating the production of IgE antibodies, which attach to mast cells and basophils resulting in an allergic reaction.